Advances in cord blood transplants in adults by Doan, Phuong L & Chao, Nelson J
Advances in cord blood transplants in adults
Phuong L Doan
1 and Nelson J Chao
1,2*
Addresses:
11146 N Pavilion Department of Medicine, Division of Cellular Therapy, Duke University Medical Center,
Durham, NC 27710, USA;
21146 N Pavilion Department of Immunology, Duke University, Durham, NC 27710, USA
*Corresponding author: Nelson J Chao (nelson.chao@duke.edu)
2010, 2:12 (doi:10.3410/M2-12)
The electronic version of this article is the complete one and can be found at: http://f1000.com/reports/medicine/content/2/12
Abstract
Umbilical cord blood is an acceptable source of hematopoietic stem cells for patients with malignant
diseases but has limitations in its use. In this review, we will discuss these limitations and the recent
advances in cord blood transplants that may enable cord blood to become more widely available as an
alternative stem cell source for adults for the treatment of malignant diseases and for use in
regenerative medicine.
Introduction and context
High-dose chemotherapy with hematopoietic stem cell
(HSC) rescue is a potential cure for patients with
hematologic diseases, but only one-third of patients
will have suitable matched related donors. Because of
this limitation, alternative stem cell sources such as cord
blood have been studied [1,2]. Umbilical cord blood was
introduced as an alternative source of allogeneic HSCs
after the success of cord transplantation in a child with
Fanconi’s anemia [3]. Since then, over 8000 cord blood
transplantations have been performed internationally.
We will highlight key studies of cord blood transplants in
adults.
The selection for the best cord blood unit is based on
human leukocyte antigen (HLA) matching 6/6 and a
nucleated cell dose of more than 3 × 10
6 cells per
kilogram [4]. Because this cell dose is difficult to achieve
in adults by using a single cord unit, two cord blood
units rather than one partially HLA-matched unit has
been studied and shown to have a median engraftment
of 23 days and have disease-free survival at 1 year in 57%
of patients but carries an increased risk of acute graft-
versus-host disease (GVHD) [5]. The increased risk of
GVHD is associated with three risk factors: (a) the use of
two units compared with one unit, (b) a nonmyeloa-
blative preparative regimen compared with myeloabla-
tive regimens, and (c) the lack of antithymocyte globulin
in the preparative regimen [6]. Because of the risk of
acute GVHD, dual-cord transplants result in higher early
transplant-related mortality compared with single-cord
transplants but have less transplant-related mortality
at 1 year and may have greater graft-versus-leukemia
effect [7,8]. To clarify these issues, randomized studies of
dual-cord versus single-cord transplants in pediatric
populations are under way. To date, however, the role
of dual-cord versus single-cord transplants in adults
remains unclear.
Because myeloablative conditioning regimens in cord
blood transplants result in high transplant-related
mortality, nonmyeloablative regimens have been studied
to determine whether reliable engraftment can be
achieved with less toxicity [9-11]. These nonmyeloabla-
tive regimens in cord blood transplants have yielded
similar results for safety, engraftment, and survival when
compared with matched sibling donors [12,13]. In a
recent review, Cutler and Ballen [14] discussed these
issues in more detail. Based on these studies, nonmye-
loablative conditioning regimens have been shown to be
a feasible alternative for patients who otherwise would
not have been able to tolerate myeloablative regimens.
Recent advances
In this section, we will discuss the use of cord blood
transplantations in regenerative medicine and evaluate
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purpose of using stem cells in regenerative medicine is to
restore normal or improved physiology to damaged
organs. Embryonic stem cells, fetal tissue stem cells,
adult tissue stem cells, and umbilical cord blood stem
cells have been evaluated for these studies [15]. Of these
stem cells, cord blood stem cells carry several advantages
since they are readily available and pose no risk to
donors for collection. In preclinical studies, cord blood
stem cells have been shown to form long-lasting blood
vessels in vivo (thus holding potential in wound-healing
models), form cardiomyocytes in acute myocardial
ischemia models, and reduce neurologic deficits in
stroke injury models [16-18]. While these studies hold
promise, they have not been translated into prospective
clinical studies due to the high toxicity of immune
suppression and high transplant-related mortality.
To overcome the limitation of low cell dose and delayed
engraftment in cord blood transplants, ex vivo expansion
of HSCs in cord blood has been extensively studied and
recently reviewed [19,20]. Initial studies were disappoint-
ing with the expansion of committed rather than
primitive HSCs. Co-culture of HSCs with early-acting
cytokines such as stem cell factor, FMS-related tyrosine
kinase, and thrombopoietin yields the greatest expan-
sion, with the most prolific expansion reported to be
146,000-fold [21]. One of the first clinical studies to
evaluate the safety and feasibility of using ex vivo
expansion of cord blood cells with cytokines in patients
withhematologicmalignanciesandbreastcancerdemon-
strated a 100% neutrophil engraftment but resulted in an
increased risk of acute grade III-IV GVHD compared with
patients who had received unmanipulated blood [22,23].
At this time, additional clinical studies are required
before cellular expansion can be done routinely.
Implications for clinical practice
The innovative use of dual-cord blood units and the
feasibility of nonmyeloablative regimens to treat patients
allow more patients to undergo transplantation with the
hope of achieving a cure. It has already been shown that
cord blood transplants have similar disease-free survival
and transplant-related mortality when compared with
matched unrelated bone marrow transplants in children
and adults [24,25]. For now, it is still to be determined
whether cord blood should be preferred over matched
unrelated donor or partially matched donor cells. Also,
specific diseases and disease stages for which cord blood
is preferred over these other cell sources are still
unknown. With the growing number of adult patients
receiving cord blood transplants, we hope to be able over
the next few years to clarify when cord blood is the best
donor cell choice for allogeneic transplantation.
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